NCT04077463 2026-03-17Chrysalis-2Janssen Research & Development, LLCPhase 1 Active not recruiting701 enrolled
NCT06106802 2026-02-23Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentSamsung Medical CenterPhase 2 Recruiting47 enrolled